Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy.

Antimicrobial Agents and Chemotherapy
Xia LuoVarun Garg

Abstract

This was an open-label, single-sequence trial in hepatitis C virus-negative volunteers on stable, individualized, buprenorphine maintenance therapy. Telaprevir at 750 mg every 8 h was coadministered with buprenorphine/naloxone (4:1 ratio as sublingual tablets) for 7 days with food. Pharmacokinetic profiles of buprenorphine, norbuprenorphine, and naloxone were measured over the 24-hour dosing interval on day -1 (buprenorphine/naloxone alone, reference) and day 7 of telaprevir coadministration (test). Geometric least-squares mean ratios and associated 90% confidence intervals of treatment ratios (test/reference) were calculated using log-transformed pharmacokinetic parameters. Opioid withdrawal symptoms were evaluated throughout the study (via questionnaires and pupillometry). Pharmacokinetic data were available for 14 and 13 volunteers on day -1 and day 7, respectively. The area under the concentration-time curve (AUC) for buprenorphine was unchanged and the maximum concentration of drug in serum (C(max)) for buprenorphine, C(max) and AUC for norbuprenorphine, and C(max) naxolone were modestly decreased during coadministration with telaprevir. Geometric least-squares mean ratios (90% confidence intervals) for buprenorphine were ...Continue Reading

References

Aug 20, 2003·Journal of Psychoactive Drugs·Donald R Wesson, Walter Ling
Mar 4, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nicolas PicardPierre Marquet
Dec 31, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Yan ChangElinore F McCance-Katz
Nov 17, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elinore F McCance-KatzPetrie M Rainey
Dec 14, 2011·Journal of Clinical Pharmacology·Varun GargRolf P G van Heeswijk

❮ Previous
Next ❯

Citations

Apr 5, 2013·Clinical Pharmacokinetics·Tony K L KiangMary H H Ensom
Oct 16, 2013·Peptides·Richard J Bodnar
May 16, 2013·BMC Gastroenterology·Sanjeev SockalingamDavid Wong
Aug 2, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stefan Mauss, Hartwig Klinker
Aug 2, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Geert RobaeysUNKNOWN International Network on Hepatitis in Substance Users
Dec 18, 2013·International Journal of Antimicrobial Agents·Johanna WeissWalter Emil Haefeli
May 13, 2014·European Journal of Clinical Pharmacology·Sarah Talavera PonsArmand Abergel
Feb 6, 2016·The International Journal on Drug Policy·Jason GrebelyUNKNOWN l’International Network on Hepatitis among Substance Users (Réseau international sur l’hépatite chez les consommateurs de dr
Jan 11, 2016·The International Journal on Drug Policy·Jason GrebelyUNKNOWN im Namen vom International Network on Hepatitis care in Substance Users
Aug 19, 2015·The International Journal on Drug Policy·Jason GrebelyUNKNOWN International Network for Hepatitis in Substance Users
May 4, 2016·Expert Opinion on Drug Metabolism & Toxicology·Onyema OgbuaguR Douglas Bruce
Oct 9, 2016·Psychiatry Research·Marta Martin-Subero, Crisanto Diez-Quevedo
Apr 24, 2015·The Annals of Pharmacotherapy·Leonie MeemkenAnton Gillessen
Oct 4, 2014·World Journal of Gastroenterology : WJG·Amber Arain, Geert Robaeys
Oct 6, 2018·Hepatology, Medicine and Policy·Jean-Michel DelileDaniel Dhumeaux

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

© 2021 Meta ULC. All rights reserved